Sincalide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Sincalide
- Sincalide (DB09142): From an Undetermined Original Indication to “Malignant Catarrh” — A Low-Confidence Signal
Sincalide (DB09142): From an Undetermined Original Indication to “Malignant Catarrh” — A Low-Confidence Signal
One-Sentence Summary
Sincalide’s original indication and mechanism of action are not available in the current evidence pack, and it is not marketed locally (0 licenses on file). The TxGNN model’s top-ranked prediction is Malignant Catarrh (a bovine herpesvirus disease), but this signal is supported by 0 clinical trials and 0 publications, and the model’s own rationale flags it as likely knowledge-graph noise rather than a genuine mechanistic finding.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No data available (evidence pack lists no approved indication; drug is not marketed locally) |
| Predicted New Indication | Malignant Catarrh (rank 1) |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data for sincalide is not available in this evidence pack, and no original indication is on record. Without a documented drug class or established indication to anchor a mechanistic comparison, the biological plausibility of the top prediction cannot be substantiated from the data provided.
More importantly, the evidence pack’s own rationale for the rank-1 candidate states that Malignant Catarrhal Fever is a herpesvirus infection of cattle with no known biological connection to cholecystokinin/gallbladder-pancreatic signaling pathways, and explicitly characterizes the high TxGNN score as likely knowledge-graph noise arising from an animal-disease node rather than a real pharmacological signal. The same pattern repeats for ranks 2, 4, 6, 7, 8, 9, and 10 — all L5, all zero evidence, several of them veterinary or genetically unrelated conditions (bovine rhinotracheitis, thrombotic disease, familial hypercholesterolemia, Prinzmetal angina, amenorrhea).
The only candidates with any literature support (rank 3: cytomegalovirus infection; rank 5: hyperthyroidism) reach only L4, based on unrelated basic-science studies on pancreatic acinar cell exocytosis and thyroid-status effects on Ca²⁺ signaling in rats — mechanistically tangential and explicitly noted as indirect/off-topic by the source rationale. No candidate in this list reaches a level where human translational relevance can be inferred.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
Sincalide has 0 licenses on file and is currently not marketed. No NDA, product, or approved-indication records are available for review.
Safety Considerations
Please refer to the package insert for safety information.
(Note: key warnings, contraindications, and DDI data are all flagged as blocking data gaps — see Conclusion below.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Malignant Catarrh) has zero clinical trial or literature support and is explicitly assessed as a likely graph-noise artifact with no plausible mechanistic link to sincalide. All ten ranked candidates are L4–L5, and none reach a level of evidence sufficient to justify advancing to safety screening (S1). In addition, a Blocking data gap (DG001: TFDA warnings/contraindications unavailable) independently prevents any safety evaluation regardless of indication strength.
To proceed, the following is needed:
- TFDA label data (warnings, contraindications) — required to clear Blocking gap DG001 before any S1 safety review
- Confirmed mechanism of action via DrugBank — required to clear High-severity gap DG002
- Documentation of sincalide’s actual original/approved indication(s), currently absent from the evidence pack
- If repurposing is still of interest, re-run evidence collection focused on ranks 3 and 5 (CMV infection, hyperthyroidism) only after confirming a plausible human mechanistic pathway — current literature for both is indirect, animal-only, and insufficient on its own
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.